Stay updated on Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page
- CheckyesterdayChange DetectedThe Study Record Dates section now shows Revision: v3.6.5, indicating a new revision of the page entry. No study details, enrollment information, or eligibility criteria appear to be altered.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check16 days agoChange DetectedThe page revision was updated from v3.6.3 to v3.6.4, signaling a new version of the page. This indicates a maintenance update without altering the study information.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe study record includes metadata updates: a new last update date, revised estimated study completion dates, and removal of the old registry identifier, with other historical dates added. These changes update timeline and registry references but do not modify treatment, eligibility, or participating locations.SummaryDifference0.4%

- Check37 days agoChange DetectedPage revision updated from v3.6.2 to v3.6.3, indicating a minor platform update. This change does not affect study content, eligibility, or outcomes.SummaryDifference0.1%

- Check45 days agoChange DetectedThe page now displays Revision: v3.6.2, replacing the previous v3.6.0. This signals a minor update to the page version rather than a change to the study content.SummaryDifference0.1%

- Check59 days agoChange DetectedRecruitment status is updated to indicate enrollment is closed, with the addition of guidance sections for reading the study record and joining a study; the page also shows an updated Intervention/Treatment header and a new revision note (Revision: v3.6.0).SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.